Xenon Pharmaceuticals’ lead drug greatly reduced the frequency of seizures in a Phase 3 epilepsy study, supporting the company’s plans to file for FDA approval in the third quarter.

The drug, azetukalner, would be Xenon’ …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844